BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38196303)

  • 1. Hemophagocytic lymphohistiocytosis induced by nivolumab/ipilimumab combination therapy: A case of lung adenocarcinoma that responded to early steroid pulse therapy.
    Hagiwara S; Tanizaki J; Hayashi H; Komeda Y; Nishida N; Yoshida A; Yamamoto T; Matsubara T; Kudo M
    Cancer Rep (Hoboken); 2024 Feb; 7(2):e1960. PubMed ID: 38196303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophagocytic lymphohistiocytosis with advanced malignant melanoma accompanied by ipilimumab and nivolumab: A case report and literature review.
    Mizuta H; Nakano E; Takahashi A; Koyama T; Namikawa K; Yamazaki N
    Dermatol Ther; 2020 May; 33(3):e13321. PubMed ID: 32191382
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab.
    Hantel A; Gabster B; Cheng JX; Golomb H; Gajewski TF
    J Immunother Cancer; 2018 Jul; 6(1):73. PubMed ID: 30012206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective Treatment of a Melanoma Patient with Hemophagocytic Lymphohistiocytosis after Nivolumab and Ipilimumab Combined Immunotherapy.
    Pacholczak-Madej R; Grela-Wojewoda A; Lompart J; Żuchowska-Vogelgesang B; Ziobro M
    Prague Med Rep; 2022; 123(1):35-42. PubMed ID: 35248163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy.
    Chin CK; Hall S; Green C; Van Hazel G; Spagnolo D; Cheah CY
    Eur J Cancer; 2019 Jul; 115():84-87. PubMed ID: 31129384
    [No Abstract]   [Full Text] [Related]  

  • 6. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
    Sadaat M; Jang S
    J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in a patient with chronic lymphocytic leukemia.
    Ali SB; Kuss B; Karapetis C; Hughes T; Smith A
    Immunotherapy; 2023 Dec; 15(18):1531-1537. PubMed ID: 37933523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First case of hemophagocytic lymphohistiocytosis secondary to cabozantinib with checkpoint inhibitors.
    Azari AE; Stratton R; Singh A
    Rheumatology (Oxford); 2021 May; 60(5):e167-e168. PubMed ID: 33280022
    [No Abstract]   [Full Text] [Related]  

  • 9. Myocarditis as an immune-related adverse event following treatment with ipilimumab and nivolumab combination therapy for metastatic renal cell carcinoma: a case report.
    Miyauchi Y; Naito H; Tsunemori H; Tani R; Hasui Y; Miyake Y; Minamino T; Ishikawa R; Kushida Y; Haba R; Sugimoto M
    J Med Case Rep; 2021 Oct; 15(1):508. PubMed ID: 34649593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemophagocytic lymphohistiocytosis as a complication of combination anti-PD-1 and anti-CTLA-4 checkpoint inhibitor immunotherapy for metastatic melanoma, and the outcome of rechallenge with single-agent anti-PD-1 immunotherapy.
    Holmes Z; Courtney A; Hiong A
    BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35948362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma.
    Akagi Y; Awano N; Inomata M; Kuse N; Tone M; Yoshimura H; Jo T; Takada K; Kumasaka T; Izumo T
    Intern Med; 2020 Apr; 59(8):1075-1080. PubMed ID: 32009093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature.
    Rubio-Perez J; Rodríguez-Perez ÁR; Díaz-Blázquez M; Moreno-García V; Dómine-Gómez M
    J Med Case Rep; 2022 Oct; 16(1):365. PubMed ID: 36195892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.
    Kurozumi A; Takahashi H; Watanabe T; Iwasaki Y
    Thorac Cancer; 2021 May; 12(10):1625-1628. PubMed ID: 33783978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review.
    Dupré A; Michot JM; Schoeffler A; Frumholtz L; Baroudjian B; Delyon J; Lebbe C; Lambotte O
    Br J Haematol; 2020 Jun; 189(5):985-992. PubMed ID: 32243578
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases.
    Xu Z; Li H; Yu X; Luo J; Zhang Z
    Hematology; 2024 Dec; 29(1):2340144. PubMed ID: 38606818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hemophagocytic lymphohistiocytosis caused by hematogenous disseminated pulmonary tuberculosis: A case report].
    Li QY; Liang Y; Dai NN; Wang YX; Zhu BT; Wu R; Zhu H; Sun YC
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1219-1223. PubMed ID: 36533359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
    Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
    Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab-ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment.
    Bir Yucel K; Sutcuoglu O; Yazıcı O; Yıldız Y; Şenol E; Uner A
    J Oncol Pharm Pract; 2023 Apr; 29(3):760-763. PubMed ID: 35938177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS) in a patient with oncogene-addicted metastatic non-small cell lung cancer (NSCLC) following combination chemotherapy-immunotherapy.
    Heynemann S; Vanguru V; Adelstein S; Kao S
    Asia Pac J Clin Oncol; 2024 Apr; 20(2):315-318. PubMed ID: 36562695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.